Talkspace SPAC Presentation Deck

Made public by

sourced by PitchSend

11 of 20

Creator

Talkspace logo
Talkspace

Category

Healthcare

Published

January 2021

Slides

Transcriptions

#1Exhibit 99.2 January 2021 THERAPY FOR ALL talk space#2Disclaimer This investor presentation (his Presentation) has been prepared for use by Hudson Executive Investment Corp (Hudson) and Groop Internet Platform, Inc. (bis Takspace) The Company') in connection with their proposed business combination (the Business Combination) This presentation is for informational purposes only and may not be reproduced or redistributed in whole or in part without the prior written consent of Hudson and Talkspace. The information contained herein does not purport to be al-inclusive and none of Hudson, the Company of their respective affiliates makes any representation or warranty, express or implied, as to the accuracy, completeness or reliability of the information contained in this Presentation This Presentation does not constitute () a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed Business Combination or () an offer to set, a solicitation of an offer to buy or a recommendation to purchase any security of Hudson, the Company. or any of their respective affiliates, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. You should not construe the contents of this Presentation as legal sax, accounting or investment advice or a recommendation. You should consult your own counsel and tax and financial advisors as to legal and related matters concerning the matters described herein, to the extent you deem necessary Certain statements in this Presentation may be considered forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Helm Act of 1995 Forward-looking statements generally relate to future events or Hudson's or the Company's future financial or operating performance. For example, projections of future EBITDA and other metrics are forward-looking statements in some cases, you can identity forward-looking statements by terminology such as "may should expeor, nend wir estimate "anticipate believe predior, "potential" or "continue", or the negatives of these lems or variations of them or similar temminciogy. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements These forward-looking statements are based upon estimates and assumptions that while considered reasonable by Hudson and its management, and the Company and its management as the case may be, are inherently uncertan. Nothing in this Presentation should be regarded as a representation by any s y person that the forward-looking statements set forth herein will be achieved at any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Neither Hudson nor the Company undertakes any duty to update these forward-looking statements No SAP Financial M This Presentation includes certain financial measures not presented in accordance with generally accepted accounting principles (GAAP) including, but not limited to, EBITDA and certain ratios and other metrics derived there from. These non-GAAP financial measures are not measures of financial performance in accordance with GAAP and may exclude tems that are significant in understanding and assessing the Company's financial results. Therefore, these measures should not be considered in isolation or as an atemative to net income, cash flows from operations or other measures of profitability, liquidity or performance under GAAP. You should be aware that the Company's Presentation of these measures may not be comparable to similarly-tied measures used by other companies The Company believes these con-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to the Company's financial condition and results of operations. The Company believes that the use of these non- GAAP francial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends in and in comparing the Company's financial measures with other similar companies, many of which present similar non-GAAP financial measures to investors. These non- GAAP financial measures are subject to inherent Imitations as they reflect the exercise of judgments by management about which expense and income are excluded or included in determining these non-GAAP financial measures. Please refer to footnotes where presented o ed on each page of this Presentation or to the tables therein for a reconciliation of these measures to what the Company believes are the most directy comparable measure evaluated in accordance with GAAP This Presentation also includes certain projections of non-GAAP financial measures. Due to the high variability and difficulty in making accurate forecasts and projections of some of the information excluded from these projected measures together with some of the excluded information not being ascertainable or accessible, the Company is unable to quantify certain amounts that would be required to be included in the most directly comparable GAAP financial measures without unreasonable effort Consequently, no disclosure of estimated comparable GAAP measures is included and no reconciliation of the tnancial measures is included Certain monetary amounts, percentages and other figures included in this Presentation have been subject to founding adjustments. Certain other amounts that appear in this Presentation may not sum due to rounding Use of Proto This Presentation contains financial forecasts with respect to the Company's projected financial results, including Revenue and EBITDA, for the Company's fiscal years 2000 through 2023. The Company's independent auditors have not audited reviewed, compiled or performed any procedures with respect to the projections for the purpose of their inclusion in this Presentation, and accordingly, they did not express an opinion or provide any other form of assurance with respect thereto for the purpose of this Presentation. These projections should not be relied upon as being necessarily indicative of future results. The assumptions and estimates underlying the prospective financial information are inherently uncertain and are subject to a wide variety of significant business, economic and competitive risks and uncertaintes that could cause actual results to differ materially from Those contained in the prospective financial information Accordingly, there can be no assurance that the prospective results are indicative of the future performance of the Company or that actual results will not differ materially from those presented in the prospective financial information, inclusion of the prospective financial information in this Presentation should not be regarded as a representation by any person that the results contained in the prospective financial information will be achieved andMacket in this Presentation Hudson and the Company rely on and refer to certain information and statistics obtained from third-party sources which they believe to be reliable. Neither Hudson nor the Company has independently verified the accuracy or completeness of any such third-party information Business C amendments thereto and the proxy statement / prospectus and other documents fied in connection with the proposed Business Combination, as these materials will contain important information about the Company, Hudson and the Business Combination. When available, the proxy statement/ prospectus and other relevant materials for the proposed Business Combination will be maled to stockholders of Hudson as of a record dale to be established for voting on the proposed Business Combination Stockholders will also be able to obtain copies of the preliminary proxy stitement/ prospectus, the definitive proxy statement prospectus and other documents fed with the SEC, without charge once available at the SEC's website at www.sec.gov, or by directing a request to Takapace, Broadway #007, New York, NY 10005 Pin the Hudson de basis of any investment decision of thekers andament Hudson and its directors and executive officers may be deemed participants in the solicitation of proxies from Hudson's stockholders with respect to the proposed Business Combination. A list of the names of those directors and executive officers and a description of their interests in Hudson is contained in Hudson's Registration Statement on Form 5-1, as effective on June 8, 2000, which was fied with the SEC and is available free of charge at the SEC's web site at www.sec.gov, or by directing a request to Talkspace, Broadway #607, New York, NY 10025, Additional information regarding the interests of such participants will be contained in the proxy statement/ prospectus for the proposed Business Combination when available The Company and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the stockholders of Hudson in connection with the proposed Business Combination. A list of the names of such directors and executive officers and information regarding ther interests in the proposed Business Combination will be included in the proxy statement/prospectus for the proposed Business Combination when available talk space#3Oren Frank Co-founder and Chief Executive Officer talkspace talk space Today's attendees Mark Hirschhorn President, Chief Operating and Financial Officer talkspace Doug Braunstein Chairman and President Former CFO and Vice Chairman of J.P. Morgan HUDSON EXECUTIVE -INVESTMENT CORE Doug Bergeron Chief Executive Officer Technology Investor and Former CEO of VeriFone HUDSON EXECUTIVE INVESTMENT COR 2#4Hudson Executive Investment Corp. overview Founder / Managing Partner of Hudson Executive Capital Former CFO/Vice Chairman of J.P. Morgan and Head of Americas Investment Banking 35-years of M&A leadership, including some of largest Healthcare transactions HUDSON EXECUTIVE CAPITAL HEC is an investment firm that helps drive portfolio company strategy through active engagement with management Dedicated investment team with deep knowledge of public market positioning Leverage CEO network for guidance on investments HEC, along with Doug Braunstein and Doug Bergeron, is a co-sponsor of the SPAC talk space Doug Braunstein Doug Bergeron Select HEC investments AtriCure Corindus HeartWare natera tivity Managing Partner of Hudson Executive Capital 35-year successful FinTech track record including 12 years as CEO of VeriFone, during which time enterprise value grew from $50 million to over $5 billion Tech investor and mentor to management teams CEO network: Select Healthcare Executives Marc Casper: President, CEO and Director Stephen Hemsley: Former CEO and current Chairman Alan Miller: Founder, Chairman and CEO Fred Eshelman: Former Chairman and CEO Paul Ormond: Former Chairman and CEO Thermo Fisher SCIENTIFIC UNITEDHEALTH GROUP UHS PPD HCR Manor Care 3#5talk space talk space Tech-enabled solution to tremendous unmet medical need with huge TAM accelerated by COVID 6 Key highlights Platform designed to optimize outcomes for patients and clinicians 5 Ideal modality for behavioral health - more affordable and more timely access Scalable technology stack driven by unmatched behavioral data set Purpose-driven management team with proven public telehealth track record Best-in-class B2C capabilities and brand awareness Sizable B2B pipeline of incremental recurring revenue Highly attractive valuation, growth profile and unit economics Hudson Executive / Talkspace partnership further accelerates growth ■ Deep enterprise relationships in healthcare and other industries ■ Public market and M&A expertise 4#6Valuation Capabilities Compelling peer differentiation 2021E EV / Revenue 2022E EV / Revenue 2021E EV / Gross Profit 2022E EV / Gross Profit 2019-2023E revenue CAGR Clinical model focus B2C | B2B behavioral Physician continuity talk space Source: FactSet and company filings Note: Market data as of 01/07/21; Pro forma for merger with Livongo talk space 11.2x 6.8x 17.5x 10.9x 65.3% Specialized behavioral network TELADOC. 20.7x 15.2x 30.4x 22.2x 48.4% Clinician Supply / demand alignment x amwell 22.9x 18.1x 62.3x 44.6x 30.2% Clinician supply / demand alignment xx x 5#7Core Peers¹ Compelling peer differentiation EV/ EV/ Revenue Revenue 2021E 2022E Disruptive Healthcare² High Growth Internet³ talk space Telehealth/behavioral health offering • Technology-driven differentiation Disrupting long-standing therapy solutions Innovation expanding TAM Transforming business and consumer connectivity • Recurring revenue stream 19.2x 18.0x 22.8x 11.2x 14.2x 14.6x 18.1x 6.8x Revenue CAGR '19A- 22E 36% 27% 42% 75% talk space FactSet as of 01/07/2021, Core Peers includes mean of Amwell, GoodRx, SOC Telemed, Teladoc, Disruptive Healthcare includes mean of Accolade, DexCom, Health Catalyst, HealthEquity, Inspire Medical, iRhythm, Novocure, Oak Street One Medical, Phreesia, Veeva: High Growth Internet includes mean of Chegg. Etsy, Fiverr, Match, Shopify. Upwork Zoom, Note: SOC Telemed is based on capital structure at deal announcement and Teladoc is pro forma for merger with Livongo 6#8talk space 14 Amy Scarano Business Overview#9Behavioral health is a vital service with an enormous TAM 70+ million Americans suffer from mental illness, spread across all ethnic, socio- economic and age ranges 17 million US adults have had at least one major depressive episode in the past year Illustrative fully-treated global TAM¹ International TAM Domestic TAM -$480bn -$273bn $133bn $73bn 2019 30% Increase in annual US suicide rate since 2001 True Global TAM 3.5% CAGR 60% of Talkspace members are $4.6 billion $192 billion Spent annually in the U.S. on unnecessary ER visits for mental illness in therapy for the first time -$588bn -$335bn $163bn $90bn 2025 Of annual lost wages and lost productivity in U.S. as a result talkspace Source: Mordor Intelligence, NAMI, lustrative fully-treated global TAM represents total addressable market if the entire prevalent population were to receive care (only approximately 46% of patients with a behavioral illness currently receive care). This TAM number is calculated by taking the global TAM of those who receive treatment, divided by the % of the total treatable population who receive care 8#10Leading virtual behavioral health platform talk space Robust technology platform purpose-built to personalize treatment and drive outcomes Highly rated app promotes behavioral health as a lifestyle choice, not a one-time event Leading management team passionate about mission Large, optimized clinician network Unique B2C capabilities and a highly-engaged customer base Robust and rapidly expanding B2B presence 2021E financial snapshot $125M net revenue Company snapshot >2M Members served to date #1 branded virtual therapy provider -69% y/y rev. growth >39M commercial covered lives -2,650 providers talk space Source: Brand Health Tracking Study (February and July 2020): Includes B2C and 828 active members; Hull, T.D., Malgaroli, M, Connolly, P.S. et al. Two-way messaging therapy for depression and anxiety: longitudinal response trajectories. BMC Psychiatry 20, 297 (2020) -64% gross margin -46.000 active members¹ 68% Of members saw improvement in symptoms² 9#11A deep, highly experienced leadership team with both technology and healthcare expertise Oren Frank CEO, Co-Founder McCANN Roni Frank Co-Founder, Clinical Services - amdocs Dr. Neil Leibowitz Chief Medical Officer OPTUM Mark Hirschhorn President, COO and CFO TELADOC. Deb Adler SVP Network & Quality UnitedHealthcare Gil Margolin сто amdocs Nisim Cohen VP Finance and Ops EY A Sam Braunstein Chief Marketing Officer Higher ne CONCERTIV Michaela Yule Chief of Staff BAIN & COMPANY "Our mission is to provide more people with convenient access to affordable behavioral healthcare so that those in need live a happier and healthier life" talk space 10#12Access Quality ↑ Virtual therapy ideal for the unmet need in behavioral care ||||||| Elements of care Convenience Timeliness $ Cost Clinical matching Care continuity Outcomes talk space X Per Talkspace-conducted employer study X Inefficient X High cost X In person limitations Treatment stigma coupled with physical hurdles X X Lead time between appointment / visit 44% return for second visit¹ Hard to measure, variable outcomes talk space Multiple ways to access care On-demand access aligns issue and solution Affordable pricing model Matching algorithm and access to clinical network 80% return for second visit¹ COVID has accelerated and made permanent these changes Al / machine learning- driven platform 11#13B2C Overview B2B Overview Therapy $65/week Messaging Plus Text, video and audio messaging B2C and B2B model overview $79/week Messaging Premium +1 Live Video Text, video and audio messaging Employee Assistance Program ♥aetna Humana. PREMERA Cigna. Behavioral Health Average member treatment length: 5.4 months¹ Monthly average per member: $263¹ Cigna. OPTUM $99/week 99 LiveTalk Ultimate +4 Live Videos Text, video and audio messaging EAP price per session: $65 BH price per session: $70 Direct to Employer Blackstone Google accenture Psychiatry Fee per session model Initial consultation: $199 Follow-up: $125 Fee per session model Initial consultation: -$180² Follow-up: -$120² Robust growth B2C Active Members -20,000 2019A -28,000 Sustained high growth in direct to consumer member base Current Total B2B covered lives (mm) > 39 Q1'19 Current Impressive client growth success despite only recently launching talk space Numbers calculated based on most recently aggregated cohort data from January 2017 to August 2020; 282B Psychiatry pricing shown as an illustrative average, true amount varies by provider type and payer 12#14Robust growth Active providers -1,300 Jun'19 Unique platform to match providers and patients Unparalleled value proposition Efficiency 102% growth Flexibility and convenience talk space -2,650 Nov 20 Professional development $ Income Unmatched presence and quality Access -2,650 providers across all 50 U.S. states Experience Diversity 100% of providers with a Masters degree or higher 85% female, 15% male 33% people of color 8 years average years of experience per provider 21 clinical specialties 37% under age 35 13#151 2 3 5 The journey 6 Screening / intake Match 4 Outcomes Treatment Discharge Robust technology platform drives differentiated care model Maintenance Technology engaged Robust, data-supported provider network Proprietary matching algorithm and quality control Machine learning-driven tools and programmatic / predictive therapy Outcome trends and engagement patterns Clinical progress tracker and data-driven discharge results Personal digital care tools Impact Highly specialized, reliable expertise Initial behavioral health assessment to evaluate member well-being and note specific needs and preferences Personalized matches to suit specific needs and preferences Member and provider matched based on specific preferences, driving positive outcomes and retention Improved clinical outcomes Fully structured treatment incorporating a variety of evidence-based provider tools Outcomes visualization tools become iterative in treatment journey 68% of members improved or remitted in reported anxiety / depression symptoms Data results to catalyze and reinforce positive next steps Member provided with data results from sessions and reminded of support available with no interruption to prior cadence / provider Providing better therapy at scale - truly managed care talk space Source: Hull, T.D., Malgaroli, M., Connolly, P.S. et al. Two-way messaging therapy for depression and anxiety: longitudinal response trajectories. BMC Psychiatry 20, 297 (2020) 14#16Talkspace offers a best-in-class member experience Find provider Finding the right match Finding a great therapist begins with learning about what brings you to therapy and some basic information about you and what you're looking to achieve Begin Personalized matches to suit specific needs and preferences talk space **** Guaranteed response time By signing up for Talkspace you have made a really meaningful choice. I know it can be an overwhelming decision but therapy can help you become a happier you. Yeah, I'm going through a lot and it's been a struggle. I felt like I had to talk to a professional but my schedule is so busy I can't wait to get started Let Eline know you're ready for her to reply Message Elaine... ■ Secure, reliable messaging with a licensed provider Multi-platform capability 25:03 Live video sessions with providers across mobile and desktop Digital navigation and triage Clinical progress Symptom tracker Depression None-Low While you do not have symptoms, therapy can still help reduce stress and shift habies that are keeping you stuck. Learn more Long-term goals All Reduce overall frequency, Obse Likely Your sc of OCD sympto Learni Reco ■ Goal-setting, guidance, and personalized treatment plans 15#172986420 12 10 Science-based approach leads to superior clinical outcome Clinical case study Talkspace treatment efficacy Pre PHQ-9 -GAD-7 Post 68% of patients improved or remitted Methods Published study of 10,718 participants Study length of 1.5-3 months Average patient age 35 Based on PHQ-9, GAD-7 results ■ Clinical standard for measuring depression and anxiety symptoms, respectively A focus on clinical excellence 10 Peer-reviewed studies RESEARCH ARTICLE WILEY Patterns of utilization and a case illustration of an interactive text-based psychotherapy delivery system George C. Nitzburg Barry A. Farber RESEARCH ARTICLE Two-way messaging therapy for depression and anxiety: longitudinal response trajectories Message Delivery for the Treatment of Postraumatic Stress Disorder: Longitudinal Observational Study of Symptom Trajectories BMC Psychiatry Open Altess talk space Source: Hull, T.D., Malgaroli, M. Connolly, P.S. et al. Two-way messaging therapy for depression and anxiety: longitudinal response trajectories. BMC Psychiatry 20, 297 (2020) Identifying therapist conversational actions across diverse psychotherapeutic approaches F-Ti Lee, Derrick Hall, Jacob Levine, Bi Ray, Kathleen McK "Celia Unicrsity, Department of Computer Scic 16#18The strongest brand in digital behavioral health Instantly recognizable, highly influential spokespeople Highest brand awareness¹ relative to competitors Multi-faceted marketing approach is core to success in consumer market Optimized Go-To-Market Narrative + Tracked Consumer Engagement PR +Advertising / Earned Media talk space Source: July 2020 Brand survey - 1,200 U.S. consumers, 18-49 yo Measurement of aided awareness. Forbes Cigna Expands Mental Health Network With Talkspace's Virtual Therapy talk space dr. on demand MDLIVE Top US behavioral telehealth brands Print Media + Grassroots Campaign THE KEY TO SUCCESS? GOOD MENTAL HEALTH Teladoc HEALTH betterhelp Spokespeople + Employer Partnership Program Cigna Humana. 17#19talk space Rooms Sharon Adams H... 1200 PM 3 TheSLCSw I understand how this would impact your mood. It's really.. Helpful tips How do I start? Therapy tools 19= Live video sessions Next session scheduled for SPM Thursday, Nov 7 Therapy exercises Bud healthy and 9... Your journey Follow the steps and What should expect from m therapist? B Growth

Download to PowerPoint

Download presentation as an editable powerpoint.

Related

Fiscal 3Q Investor Presentation image

Fiscal 3Q Investor Presentation

Healthcare

FY23 Full-Year Results Presentation image

FY23 Full-Year Results Presentation

Healthcare

Healthcare Network P&L Statement and Expansion Projects image

Healthcare Network P&L Statement and Expansion Projects

Healthcare

Accreditation and Quality Assurance Overview image

Accreditation and Quality Assurance Overview

Healthcare

Investment Highlights image

Investment Highlights

Healthcare

Investor Presentation image

Investor Presentation

Healthcare

IDEAYA Biosciences Interim IDE397 Phase 1 Clinical Data and Q1 2022 Corporate Update image

IDEAYA Biosciences Interim IDE397 Phase 1 Clinical Data and Q1 2022 Corporate Update

Healthcare

BioAtla Investor Presentation Deck image

BioAtla Investor Presentation Deck

Healthcare